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Background: The use of substandard and degraded medicines is a major public health problem in developing
countries such as Cambodia. A collaborative study was conducted to evaluate the quality of amoxicillin–clavulanic
acid preparations under tropical conditions in a developing country.
Methods: Amoxicillin-clavulanic acid tablets were obtained from outlets in Cambodia. Packaging condition, printed
information, and other sources of information were examined. The samples were tested for quantity, content
uniformity, and dissolution. Authenticity was verified with manufacturers and regulatory authorities.
Results: A total of 59 samples were collected from 48 medicine outlets. Most (93.2%) of the samples were of
foreign origin. Using predetermined acceptance criteria, 12 samples (20.3%) were non-compliant. Eight (13.6%),
10 (16.9%), and 20 (33.9%) samples failed quantity, content uniformity, and dissolution tests, respectively.
Samples that violated our observational acceptance criteria were significantly more likely to fail the quality tests
(Fisher’s exact test, p < 0.05).
Conclusions: Improper packaging and storage conditions may reduce the quality of amoxicillin–clavulanic acid
preparations at community pharmacies. Strict quality control measures are urgently needed to maintain the
quality of amoxicillin–clavulanic acid in tropical countries.
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Developing countryBackground
Medicine plays an important role in maintaining health,
preventing disease and saving lives. However, ineffective
medicines pose great risks to individuals and even threaten
lives in emergencies [1,2]. Ineffectiveness takes several
forms, such as medicines containing less than the stated
dose of the active ingredient or containing unstated or
harmful substance(s). Similarly, fake or counterfeit medi-
cines and medicines that have been degraded or adul-
terated due to improper storage and handling may be
ineffective [3,4]. Hence, the health ministries of many* Correspondence: mohiuddin_khn@yahoo.com
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reproduction in any medium, provided the orcountries, especially developing nations, struggle to pre-
vent the circulation of substandard and counterfeit medi-
cines [5-10].
A combination of amoxicillin and clavulanic acid was
introduced in the United Kingdom in 1981 as Augmentin
and eventually became the treatment of choice for many
infections [11,12]. Amoxicillin–clavulanic acid is available
in a variety of doses: 250/125 mg (2:1), 500/125 mg (4:1),
875/125 mg (7:1), 1000/125 mg (8:1), and 2000/125 mg
(16:1). In combined preparations, 125 mg of clavulanic acid
is sufficient to inhibit β-lactamase–producing organisms.
Amoxicillin–clavulanic acid also has proven more effective
for the eradication of H. pylori than conventional mono-
therapies [13,14]. However, insufficient doses and inappro-
priate use of such potent antibiotics may lead to the
development of resistance [15].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dard and counterfeit medicines in Cambodian pharma-
ceutical markets, with prevalences ranging from 4% to
90% [5,7]. Several of these studies suggest that antibiotics
are deliberately counterfeited in some cases but uninten-
tionally degraded in others [7,16]. The improper storage
and handling of medicines in tropical countries may cause
the unintentional degradation of medicines [17]. Based on
previous studies in Cambodia, the Cambodian Ministry
of Health (MoH), and Kanazawa University decided to
conduct a collaborative study of the quality of amoxicillin–
clavulanic acid in the private pharmaceutical market under
tropical conditions in a developing country [7,9].
Methods
Selection of medication and study area
Combination tablets of amoxicillin–clavulanic acid were
selected from the essential medicine list of Cambodia in
consultation with the country’s MoH. Of the various for-
mulations of amoxicillin-clavulanic acid, only tablets ap-
pear on the essential medicine list of Cambodia. Because
this study did not involve human subjects, ethical clearance
was not sought. However, a memorandum of understan-
ding was signed by the Cambodian MoH before com-
mencement. Equal numbers of samples were collected
from urban and rural areas. Seven districts of the capital
(Phnom Penh) were selected to represent urban areas,
and three provinces (Kandal, Takeo, and Kampong Speu)
were selected to represent rural areas. The locations were
selected after taking into account population density, the
number of outlets, and budgetary limitations. The selec-
tions were made in consultation with the Department of
Drugs and Food and the National Health Product Quality
Control Center.
Collection of samples
Sampling was conducted in July-August 2009 by two
teams. Each team consisted of three members: a researcher,
a locally recruited supervisor and an assistant. All members
of the sampling teams were provided with training before-
hand and instructed to pose as typical customers. Stratified
random sampling was used to collect samples from four
types of private drug outlet (Pharmacy, Depot-A, Depot-B
and nonlicensed outlets). A sampling form was completed
for each sample after payment. Each sample was then




Primary and secondary packaging and printed labels were
carefully observed with the naked eye at the Department
of Drug Management and Policy, Kanazawa University,
Japan. Samples were classified into five types accordingto package type and the presence of desiccants (e.g.,
silica gel):
Type A: Press-through packaging (PTP) of aluminum-
aluminum materials in cardboard boxes.
Type B: Type A tablets wrapped in transparent plastic
with silica gel.
Type C: Type A tablets wrapped in aluminum with
silica gel.
Type D: Similar to Type C, but with PTP made of an
aluminum-plastic composite.
Type E: Strip packaging (SP) in cardboard boxes
without silica gel.
Samples having any of the following packaging defects
were considered unacceptable: 1) PTP/SP packaging with
peeling of the cover; 2) missing tablet(s); 3) PTP/SP with-
out any clear pocket breaks.
Authenticity
A database of manufacturer addresses was prepared using
labels, online searches, e-mail and telephone communica-
tion. Portions of all samples were sent to the manufacturer
with a request for authentication. Furthermore, the med-
ical regulatory authorities (MRAs) of the manufacturers’
countries were queried on the legitimacy of the manufac-
turers and their products. Taking into consideration the
WHO definition of counterfeit medicines, all information
was then cross-checked to arrive at a final determination
on the authenticity of the samples and their manufac-
turers [9,18].
Chemical analysis
Dosage and uniformity tests were conducted on 10 tablets
according to the United States Pharmacopoeia (USP 30)
by high-performance liquid chromatography. A Shim-pack
CLC-ODS (M) 15 cm column (Shimadzu, Kyoto, Japan)
was used. Dissolution tests were conducted on 6 tablets
for each sample using an NTR-VS6P dissolution tester
(Toyama, Osaka, Japan) according to USP 30. For quan-
tity tests, tablets were expected to contain 90-120% of
the labeled dose. The maximum value accepted in the
content uniformity test was 15.0. For dissolution tests,
≥ 85% of the labeled dose of amoxicillin, and ≥ 80% of
the labeled dose of clavulanic acid was expected to dis-
solve in 30 minutes, respectively [19,20].
A stability test was conducted on amoxicillin/clavulanic
acid at 37°C with 100% relative humidity (RH). We used
one control sample with no visible defect, one with torn
wrapping but no strip defect, and one in which the
strips were deliberately perforated. In all three samples,
amoxicillin and clavulanic acid contents were measured
at 0, 24, 48, 72, and 96 hours. These times were based
on an exploratory experiment: significant degradation of
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conditions (37°C, 100% RH) (unpublished report).
Statistical analysis
Data analysis was performed using SPSS version 17.0.0
(SPSS Inc., Chicago). When appropriate, Fisher’s exact
test and the Bonferroni multiple t-test were used to test
the significance of differences in categorical and quanti-
tative variables, respectively. Statistical significance was
evaluated at the 5% level.
Results
Medicine outlets
A total of 59 samples were collected from 48 outlets in
Phnom Penh and surrounding provinces. Of these sam-
ples, 26 (44.1%) were collected from Phnom Penh, and
the rest from the provinces. Forty-eight (81.4%) of the
samples were from licensed outlets (31 (52.5%) Pharmacy,
4 (6.8%) Depot A and 13 (22%) Depot B); the rest (11/
18.6%) were from unlicensed outlets. At least one pharma-
cist was found to be present in 14 of the pharmacies.
Air conditioning was present in only one pharmacy. A
Cambodian registration number was found on 93.2% of
the samples. No sample was past the expiration date.
Package condition
According to the printed information, most of the sam-
ples (55, 93.2%) were imported. Only four (6.8%) sam-
ples were manufactured domestically. Fourteen (23.73%)
of the samples were branded, and the rest (45, 76.27%)
were generic. Fifty-seven (96.6%) of the samples were of
500 mg/125 mg strength, and the rest were 875 mg/
125 mg. The labels on 16 samples recommended storage
below 25°C; most others simply recommended avoidance
of humid conditions. On one product, storage below 15°C
was recommended.
On observation of all samples, 32 (54.2%) from six man-
ufacturers were categorized as type A, six (10.2%) from
one manufacturer as type B, 2 (3.4%) from one manufac-
turer as type C, eight (13.6%) from four manufacturersTable 1 Results of observational tests
Type No. of manufacturers No. of samples No. of sample
a
A 6 32 2
B 1 6 0
C 1 2 0
D 4 8 0
E 4 11 0
Total 16 59 2
* Identified packaging defects:
a = PTP/SP packaging with peeling of the outer plastic or aluminum cover.
b =missing tablet(s) in intact PTP or SP.
c = PTP/SP without clear pocket breaks.as type D and 11 (18.6%) from four manufacturers as
type E (Table 1). We found 12 (20.3%) samples with de-
fective packaging. Two samples had the plastic covers
peeled off the strips, one had a strip with missing tab-
lets, and nine had an unclear scored line of package
break for individual tablets (Table 1). There was a sig-
nificant association between the presence of instruc-
tions on humidity and the pass rate in the observational
test (p < 0.05). No significant association was found be-
tween the results of the observational test and any of the
following parameters: sampling location, shop category,
registered or unregistered store, country of origin, branded/
generic product or condition of packaging (intact or sealed
and unsealed or open).
Authenticity
Requests were sent asking 15 manufacturers to authenticate
57 products. One manufacturer could not be contacted. Six
manufacturers responded for 28 (49.1%) of the samples.
All of these samples were described as authentic. Only
three of 11 MRAs replied to our requests for verification
of the legitimacy of manufacturers and samples.
Quality analysis
Of 59 samples, eight (13.6%), 10 (16.9%), and 20 (33.9%)
failed the dose, content uniformity and dissolution tests,
respectively. No significant relationship was observed be-
tween failure rate and area of collection, shop category,
registration status, origin, branded/generic product type,
intactness of packaging (i.e., sealed or opened) or response
to authenticity investigation. However, failure rates in
the quality tests were significantly associated with the
outcome of observational analysis (Fisher’s exact test,
p < 0.05; Table 2).
Interestingly, clavulanic acid accounted for most failures
in the quantity and content uniformity tests (87.5% and
70% of failures, respectively), whereas amoxicillin accounted
for most failures (80%) in the dissolution tests. Most of
the samples (7 of 8 and 9 of 10, respectively) that failed
the quantity and uniformity tests, as well as all (20)s with packaging defects* No. of total failed samples (%)
b c
0 4 6 18.8
0 3 3 50.0
0 0 0 0.0
0 0 0 0.0
1 2 3 27.3
1 9 12 20.3

















Passed Failed Passed Failed Passed Failed Passed Failed
Condition of
packaging
No defects 46 1 p < 0.05 44 3 p < 0.05 35 12 p < 0.05 33 14 p < 0.05
Defects 5 7 5 7 4 8 2 10
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The results of the stability test suggest that both amoxi-
cillin and clavulanic acid decompose significantly within
one day (Bonferroni’s multiple t-test, P < 0.05, Figure 1).
Discussion
Medicine outlets
Public medical services in Cambodia still struggle with a
lack of medical staff in hospitals, and there are other
problems such as long waiting times and high costs [21].
The sale of antibiotics without a prescription for the treat-




























Figure 1 Changes in concentrations of amoxicillin and clavulanic acid
represents the mean ± SD of three experiments. *Significant difference (p < 0
in the concentration of amoxicillin in tablets (n=3) with each packaging cond
experiments. *Significant difference (p<0.01) compared to baseline using Bon
in tablets (n=3) with each packaging condition during storage (B). Each value
(p<0.01) compared to baseline using Bonferroni’s multiple t-test.and clinics [22]. Seeking health care in the private sector
as a first choice is widely observed in many developing
countries [23]. Our study found a prescription regulation
warning on the packaging of less than half (40.7%) of the
samples. The inappropriate use of antibiotics without
prescription may promote resistance to even the newest
and most effective antibiotics [24]. Sample collection
was conducted in July-August, when average daytime
temperatures were 30-40°C with high humidity. Al-
though there were recommended storage conditions in
the package inserts of several samples, air conditioning
was found in only one pharmacy out of 54 outlets.4
a control
b opened pillow package
c opened pillow package and PTP with 
hole
(n = 3) in each packaging condition during storage. Each value
.01) compared to baseline using Bonferroni’s multiple t-test. A. Changes
ition during storage (A). Each value represents the mean ± SD of three
ferroni’s multiple t-test. B. Changes in the concentration of clavulanic acid
represents the mean ± SD of three experiments. *Significant difference
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ments should not be supplied by outlets that cannot com-
ply with storage requirements [25,26].
Condition of packaging
Pharmaceutical packaging is an important part of the
overall manufacturing and distribution process. Good
packaging can ensure the quality and effectiveness of its
contents [27]. Several of the samples in this study had
no clear-cut break lines between tablets; thus, adjacent
tablets may be exposed to air when a tablet is torn from
a strip. Two samples that failed the observational test due
to peeling of the outer plastic or aluminum cover might
have been affected by improper handling during distri-
bution. One sample that failed due to missing tablets in
intact PTP and 9 samples that failed due to indistinct
pocket breaks may have resulted from poor manufactu-
ring practices. Ten of these samples also failed one of
the quality tests. Hence, these 10 samples are not counter-
feit but rather degraded authentic products. Strict adhe-
rence to good manufacturing, distribution, and pharmacy
practices may improve the quality of medicines for end
users [27].
Authenticity
This study received few responses from MRAs and man-
ufacturers, which may be due to the methodology used
in the authenticity investigation. This issue is a low pri-
ority for manufacturers and MRAs [7]. Failed samples
were attributed to degradation; no counterfeit products
were identified. Nevertheless, cooperation from all stake-
holders is crucial to safeguard medicine quality, espe-
cially from counterfeits [7,28].
Quality analysis
Samples that failed the content uniformity test usually
came from open packages/containers during sampling
(Fisher’s exact test, p = 0.057). Moreover, samples that
failed the quality test were significantly more likely to
fail the observational test of this study (p < 0.05, Table 2).
This outcome indicates that appropriate storage condi-
tions and packaging may help prevent deterioration in
the quality and bio-availability of medicines. Some previous
studies also reported damaged packaging as a prominent
characteristic of counterfeit and substandard medicines
[15,29].
Clavulanic acid is volatile and unstable when exposed to
high temperatures and high pH [30]. In addition, clavulanic
acid is hygroscopic; therefore, 30% RH or less is desirable
for storage [31,32]. The harmful effects of experimentally
introduced packaging defects on amoxicillin–clavulanic
acid revealed here were in accord with recent studies:
clavulanic acid was the main factor in the degradation of
mixtures [33-35]. Our results show that several samplesfailed the quantity and content uniformity tests because
of low clavulanic acid contents. Degradation of clavulanic
acid may occur during manufacturing, in distribution, or
in storage at the pharmacy. Packaging practices and mate-
rials have been reported to contribute to the degradation
of medicines in several studies [19,36]. Improvement and
standardization of packaging, as well as strict compliance
with good distribution and pharmacy practices, may help
to maintain the quality of medicines for the end user.
Most of the samples that failed the quality tests in this
study were generic. The circulation of substandard generic
amoxicillin-clavulanic acid was reported in two recent
studies in other countries [37,38]. Some reports suggest
that different coatings and additives with similar active in-
gredients are used to make medicines bio-available [39].
Therefore, the low dissolution rate of amoxicillin observed
in this study might be due to the additives used in generic
formulations. There is evidence that poor-quality medi-
cines commonly fail dissolution tests, which is in accord
with our findings [40].Limitation
We did not measure potassium content; this omission
could be considered a limitation of this study. This deci-
sion was made because of the low number of tablets in
each samples and limited resource. Analysis of potassium
might provide important clues as to whether the degra-
dation of clavulanic acid occurred in the supply chain or at
the manufacturer. One objective of this study is to check
quality authenticity and pharmacopoeial quality within the
framework of limited collected samples and resource and
quickly report these values for necessary measures, even in
cases of incomplete investigation of the cause and source
of such medicines. Another limitation of this study was
the absence of liquid formulations such as syrups and sus-
pensions due to our selection criteria. Further study is re-
quired to evaluate these commonly used products.Conclusion
This study shows that the condition of packaging is an im-
portant factor in maintaining the quality of amoxicillin–
clavulanic acid products. To ensure quality, manufacturers
must comply with GMP requirements. Distributors and
service providers also need to be very stringent in adhe-
ring to quality assurance and standard operating procedures.
It may not be possible to completely eliminate antibiotic re-
sistance; however, through the improved management and
rational use of antibiotics, we may be able to delay the
process.Competing interests
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